Developing Story
CRISPR CD33 Editing for Blood Cancer Transplants
A 30-patient trial showed that CRISPR-edited donor stem cells lacking the CD33 gene could help treat aggressive blood cancers while protecting healthy cells from CD33-targeted therapy, a notable clinical advance for gene-editing medicine.
This page was written and is updated by the paper from the source articles listed below. Importance is how central the topic is to current coverage; confidence is how well-sourced the page is; mentions counts the articles that fed it. How the wiki works →
Researchers used CRISPR to remove the CD33 gene from donor stem cells, potentially giving doctors a way to attack aggressive blood cancers without destroying the healthy cells patients need after a transplant (ScienceDaily, September 25). In a 30-patient trial, the edited cells successfully took hold and appeared to shield blood cells from a CD33-targeted cancer treatment (ScienceDaily, September 25).
This represents a specific and clinically advanced application of CRISPR gene editing technology — a targeted approach to blood cancer treatment that has reached human trials. Given the ongoing strategic and commercial importance of gene-editing therapeutics, CRISPR-based treatments in clinical trials are likely to generate continued news coverage as they progress toward regulatory approval, with implications for biotech investment, IP disputes, and healthcare policy.